Here's a breakdown of the key facts from the provided text:
Main point: A test called MyPhenome,developed by Phenomix Sciences,can predict how well patients will respond to GLP-1 therapy (like semaglutide) for obesity,even after gastric bypass surgery and across diverse racial/ethnic groups.
Key Findings:
* High Accuracy: The test has a negative predictive value of 90%, meaning it's good at identifying patients who won't respond to the therapy.
* diverse populations: The test's predictive ability was demonstrated in racially and ethnically diverse populations.
* Mechanism: The test assesses the genetic integrity of the homeostatic food intake regulation pathway. A functioning pathway is needed for optimal response to GLP-1 agonists.
* Post-Surgery Submission: The test is effective in patients who have undergone Roux-en-Y gastric bypass.
Source:
* The research was presented at ObesityWeek (November 4-7, 2025, Atlanta) by Villamarin JC, et al.
* Further information is available on the Phenomix Sciences website: https://www.phenomixsciences.com/about/press